

Olanzapine-Induced Metabolic Syndrome What Can We Learn from Africa, Sudan

Dr. Abdalkhalig Mohamed Abdallah Japir and Abdelgadir Hussein Osman*

Faculty of Medicine, University of Khartoum, Khartoum, Sudan

Abstract

It is still unclear whether ethnic and cultural differences of individuals living in Africa continent would affect the emergence of the well-established findings of olanzapine related metabolic syndrome in the international literature, in ways that can be attributed to idiosyncratic, biological, cultural or otherwise. Therefore, we carried out a cross-sectional study involving 100 candidates enrolled, consecutively from two national psychiatric clinics in Khartoum, Sudan. All participants were taking Olanzapine monotherapy for a period of nine month or more. This article describes findings related to presence or absence of Metabolic Syndrome (MetS), and any medical and sociodemographic factors associated with the condition. We also, worked out the 10 year Framingham risk score for the likelihood of developing coronary heart disease for all candidates. Metabolic syndrome was found in 45% of all subjects. Moreover, candidates that presented with metabolic syndrome did so, regardless of the dose size of olanzapine, the diagnosis prescribed for or their gender. However, greater vulnerability for developing MetS, was detected in subjects with family history of diabetes. Consequently, these patients were found to have a higher 10 year Framingham risk score for coronary disease.

Keywords: Metabolic syndrome; Olanzapine; Weight gain

Introduction

Significant variation exists in the prevalence of Metabolic Syndrome (MetS), depending on the defining diagnostic criteria for the condition; the population studied and associated correlates. Regardless, the obesity epidemic is increasing the prevalence of MetS in all western countries [1]. Around 34% of people met the criteria for metabolic syndrome set by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), National Health and Nutrition Examination Survey (NHANES, 2003-2006) [2,3]. It is estimated that there has been a 5% increase in the prevalence of MetS in the last 15 years, according to the National Health and Nutrition Examination Survey (NHANES) [4,5]. Similar results were obtained by the WHO with respect to their estimates of MetS [6,7]. A high prevalence has been estimated based on the definition of the International Diabetes Federation (IDF) [8,9]. IDF definition adopted a lower cut off values for waist circumference, thus, estimated higher prevalence [10]. Despite the variation in estimating the prevalence of MetS, it is still estimated that a large majority of the population is at an increased risk of developing Diabetes Mellitus Type 2 (DMT2) and Coronary Heart Disease (CHD) [11].

The prevalence of MetS is also increasing in developing countries, with an estimated figure of 9.8% in Indian urban dwellers and 42% in urban Iranian females [12]. The increased prevalence of MetS in developing countries is associated with a shift from a traditional lifestyle to a more western lifestyle [13,14].

Multiple factors contribute to the rise in obesity and MetS in developing countries, namely epidemiological and demographic transition (demographic transition refers to the shift to low fertility, low mortality and high life expectancy; epidemiological transition means shifting from infectious diseases to diseases related to lifestyle). This shift in metabolism and body composition then increases the BMI, resulting in generalized obesity and an increase in both DMT2 and dyslipidaemia [15].

Earlier studies have found a link between some mental illnesses and MetS [16-18]. Reasons given for this connections were genetic in case of schizophrenia, beside negative psychopathology, unhealthy diet and sedentary lifestyle [19,20]. This link, however was later disputed

by findings that patients developed weight gain and MetS regardless of their diagnosis [21].

An increasing body of research suggests that weight gain and obesity due to Second Generation Antipsychotics (SGA), occurs at an early phase of treatment in patients with psychosis [22-24].

Moreover, use of atypical antipsychotics produced about four times greater likelihood for developing MS. This is of concern because atypical antipsychotics are the first- choice medications for schizophrenia [24,25].

However, little is known of MetS prevalence in Africa, and particularly in vulnerable psychiatric patients on olanzapine treatment, Therefore, this study aimed to examine whether these earlier findings regarding MetS in relation to SGA, namely olanzapine, applies equally in the cultural and geographical setting of Sudan, in Africa.

Methodology

Study design

This was a cross-sectional hospital-based study, conducted in the period from 25th January 2014 to 25th April 2014. The study was carried out at outpatient clinics of two national psychiatric hospitals in capital of Sudan (Khartoum), i.e. Eltigani Elmahi Teaching Hospital and Baashar Teaching Hospital. The former is the biggest psychiatric hospital in Sudan. Both hospitals cater for a population of 6 million, besides receiving referrals from surrounding provinces. Patients, were screened by a senior psychiatrists for confirmation of eligibility for

*Corresponding author: Abdelgadir Hussein Osman, Faculty of Medicine, University of Khartoum, Khartoum, Sudan, Tel: 002499123 12117; E-mail: abdelgadir1159@yahoo.com

Received: March 10, 2019; Accepted: March 20, 2019; Published: March 27, 2019

Citation: Japir AMA, Osman AH (2019) Olanzapine-Induced Metabolic Syndrome What Can We Learn from Africa, Sudan. J Psychiatry 22: 462. doi:10.4172/2378-5756.1000462

Copyright: © 2019 Japir AMA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

this study, using the International Classification of Disease (ICD10), criteria for confirmation of functional psychosis, as, entry criteria, beside must have been taking Olanzapine monotherapy (not combined with any other psychotropic medication) for a period of nine Month or more. We excluded from the study, pregnant women, patients with serious physical organic illness affecting their weight such as, neoplasm, anorexia nervosa and patients with interrupted adherence to treatment.

All 167 eligible patients, who attended the outpatient clinics during the study period, invited to take part in the study; 57 refused to participate, and 10 patients were too ill and lacked the capacity to provide informed consent. In total, 100 patients agreed to take part in the study, and signed a consent form.

Procedure

Participants were given verbal instructions to fast in the ward for 12 hours. Then, blood samples were taken from each participant. A research assistant took a detailed history in a semi-structured interview designed by the research team to assess for risk factors as detailed in the results. Anthropometric measures were taken according to the standardized WHO protocol (the waist was measured at the midpoint between the last palpable rib and the top of the iliac crest and the hip was measured around the widest portion of the buttocks with minimal clothing and minimal tension using a flexible non-stretchable tape). The waist-hip ratio was calculated for each subject. Height and weight were measured and the Body Mass Index (BMI) was calculated. Conventional BMI categories were used (underweight ≤ 20 , normal 20-25, overweight 25-30, and obese ≥ 30). Blood samples, were analysed by Sudan National laboratory, for blood sugar, cholesterol, Triglyceride Lipoproteins (TGL), and High Density Lipoproteins (HDL).

We used guidelines recommended by the International Diabetes Federation (IDF), to identify MS, as it gives ethnic specific values for hip and waist circumference that were used as part of the 4 other criteria for diagnosis of this condition; other risk factors, dyslipidaemia (raised triglycerides and lowered high-density lipoprotein cholesterol), elevated TGLs (≥ 150 mg/dL) or drug treatment for elevated TGL; reduced HDL-C (<40 mg/dL in males, <50 mg/dL in females) or drug treatment for reduced HDL-C; elevated Blood Pressure (BP), (systolic ≥ 130 mmHg and/or diastolic ≥ 85 mmHg) or antihypertensive treatment in a patient with Hypertension (HTN); and elevated FBG (≥ 100 mg/dL) or drug treatment for hyperglycemia.

For every participant, we calculated the Framingham risk score using the modified classic Framingham equation, with 10 year cardiovascular mortality as the endpoint. This is a probabilistic prediction of mortality *via* cardiovascular reason, using the generally known metabolic risks; thus, including the weighted risk factors age, sex, systolic blood pressure, total and high density lipoprotein cholesterol concentrations, smoking, diabetes mellitus, and electrocardiogram based left ventricular hypertrophy.

Compliance with ethical standards

“All procedures performed in studies involving human participants were in accordance with the ethical standards of Sudanese Medical Specialization Board, and, that of the Helsinki declaration 1964, and its later amendments or comparable ethical standards.”

Consent: Formal permissions were received from all relevant hospital administrations. Written consents were obtained from all participants, who were provided with an information leaflet explaining the study procedures and confidentiality.

Results

In total, 100 subjects took part in this study; 55 participants were female (55%) and 45 were male (45%). Table 1 shows the prevalence of MetS according to gender; 24 (43.6%) females met the criteria for MetS while 21 (46.6%) males fulfilled criteria for MetS, with a total of 45% of all subject showing evidence of MetS. No significant association was found between MetS and gender (p-value 0.646). Table 2 reveals the distribution of the participants, according to BMI; 45% were within the normal range, 40% were overweight, 12% were obese and 3% were within the underweight category (mean BMI 26.1).

Table 3 shows the distribution of participants according to the dose range of olanzapine; 86 patients were taking 5-10 mg olanzapine, 6 patients were taking 11-15 mg and 8 patients were on a dose of more than 15 mg a day. In this sample, we found that there was no specific association between the dose of olanzapine or the duration of treatment as long as the dose of olanzapine is 5 mg or more for a duration of nine months or more (p-value 0.56 and 0.43, respectively). Table 4 shows the distribution of the study population according to the duration of olanzapine treatment; 13 patients had been taking olanzapine for 9-12 months, 9 patients were on olanzapine for 13-16 months, 1 patient had been on olanzapine for 17-20 months, 4 patients for 21-24 months, and 73 patients had been taking olanzapine for a period of more than 24 months.

Table 5 shows the distribution of participants according to use of alcohol and cigarette smoking, Table 6 shows distribution of participants according to blood high density lipoproteins, and Table 7 shows known family history of chronic vascular disease, diabetes, and hypertension

(No=100)	No.	%
Male	45	45%
Female	55	55%

Table 1: Distribution of the study population according to gender.

Criterion		Olanzapine dose		
		5 to 10 mg	11 to 15 mg	16 to 20 mg
Metabolic syndrome	Yes	40	4	1
	No	46	4	5
Total		86	8	6
p-value 0.349				

Table 2: Distribution of metabolic syndrome according to dose range.

Criterion		Duration of olanzapine treatment in months				
		9 to 12	13 to 16	17 to 20	21 to 24	>24
Metabolic syndrome	Yes	6	4	1	1	33
	No	7	5	0	3	40
p-value 0.595						

Table 3: Distribution of metabolic syndrome according to the duration of olanzapine treatment.

Criterion		Mental illnesses		
		Affective	Schizophrenia	Schizoaffective
Metabolic syndrome	Yes	17	24	4
	No	16	35	4
Total		33	59	8
p-value 0.579				

Table 4: Distribution of metabolic syndrome according to mental illness.

Criterion		Smoke cigarettes			
		Heavy	Moderate	Light	None
Drink alcohol	Yes	0	1	1	1
	No	2	4	18	73
Total		2	5	19	74

Table 5: Distribution of smokers and non-smokers according to alcohol consumption.

Criterion		Number of participants
Triglyceride	High	56
	Normal	44
HDL	Low	53
	Normal	47

Table 6: Distribution of participants according to their triglyceride and HDL values.

First degree diseases	Chronic CVD	DM	DM & HTN	HTN	None	Total
CHD	0	0	0	0	2	2
DM	0	1	1	0	16	18
HTN	0	0	0	1	15	16
DM & HTN	0	0	0	1	6	7
DM & CVD	0	0	0	0	1	1
HTN & CVD	0	0	0	0	5	5
DM, HTN & CVD	0	0	0	1	2	3
DM, HTN & CHD	0	0	0	1	0	1
None	1	0	0	1	45	47
Total	1	1	1	5	92	100

p-value 0.223

Note: CHD: Coronary Heart Disease; DM: Diabetes Mellitus; HTN: Hypertension; CVD: Cerebrovascular Disease

Table 7: Association between chronic diseases in the participants and chronic diseases in participant's first-degree relatives.

in nearest relatives. Data from these three tables were used to determine the 10 year Framingham risk score for CHD.

Discussion

MetS has many different diagnostic criteria; in this study, we used the International Diabetic Federation criteria for two reasons: it gives ethnicity-specific reference values for waist circumference and it is an easy and accurate research tool.

Our study showed that the prevalence of MetS in Sudanese patients receiving olanzapine monotherapy for more than nine months was 45% which is in agreement with similar studies in developing countries [26-28].

Our results reveal that 30% of participants (30 patients) were not known to be diabetic but showed an impaired fasting glucose level (more than 100 mg/dL). This may indicate a diabetogenic effect of olanzapine. Similar findings have been obtained by other researchers, that they found association of olanzapine induced MetS and diabetes in individuals that otherwise did not have strong family history of diabetes [22,29,30].

Our findings highlight the important fact that olanzapine-related weight gain and MetS are not gender, age, diagnosis or dose-related side effects, as long as the individual patient has taken olanzapine for a period of more than nine months (p-values 0.595, 0.349, 0.595, respectively).

In contrast to earlier reported findings by some researchers Correl and De Hert et al. showing that MetS is severe and frequent in patients diagnosed with schizophrenia, we did not find this effect specifically linked to a diagnosis [31,32]. In fact, all patients with all forms of psychosis who were receiving olanzapine presented with MetS in equal proportions, with no specific effect to diagnosis as much as to olanzapine intake (p-value 0.579).

The Framingham risk score for the probability of developing CHD in 10 years is generally considered to be sensitive scale for estimating future cardiac risk in MetS patients [33]. The parameters of this scale include smoking, HDL, triglycerides, total cholesterol, age, gender and hypertension. In total, 40% of our subjects (40 patients) were overweight with a mean BMI of 26.1. Therefore, we found that 2 (2%) patients had more than a 16% probability of developing CHD in 10 years, 6 (6%) had a 11-15% probability, 18 (18%) had a 6-10% probability, 21 (21%) had a 1%-5% probability and 53 (53%) had a less than 1% probability. Comparable results have been found in many other studies [34-42].

Conclusion

The prevalence of MetS in Sudanese psychiatric patients receiving olanzapine monotherapy for more than nine months is 45%. The prevalence of MetS after nine months does not appear to be gender, duration, diagnosis or dose dependent. Consequently 47% of participants have had considerably high, Framingham risk score for CHD.

Recommendations

Large longitudinal controlled studies should be conducted to determine the mechanism of how olanzapine induces MetS on the molecular level and the exact associating risk factors, in order to formulate better advice, clinical decisions and patient selection. Moreover, clinical strategies to minimize the incidence of MetS and other metabolic disorders among patients taking olanzapine should be put in place in all countries.

References

- Addington J, Saeedi H, Addington D (2006) Weight gain in first-episode psychosis over three years. *Schizophr Res* 86: 335-336.
- Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 15: 539-553.
- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 120: 1640-1645.
- Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 23: 469-480.
- Alexander CM, Landsman PB, Teutsch SM, Haffner SM (2003) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes* 52: 1210-1214.
- Athyros VG, Ganotakis ES, Tziomalos K, Papageorgiou AA, Anagnostis P, et al. (2010) Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. *Curr Med Res Opin* 26: 713-719.
- Azizi F, Salehi P, Etemadi A, Zahedi-Asl S (2003) Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. *Diabetes Res Clin Pract* 61: 29-37.
- Balkau B, Charles MA (1999) Comment on the provisional report from the

- WHO consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabet Med* 16: 442-443.
9. Bruno G, Merletti F, Biggeri A, Bargerò G, Ferrero S, et al. (2004) Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. *Diabetes Care* 27: 2689-2694.
 10. Cameron AJ, Shaw JE, Zimmet PZ (2004) The metabolic syndrome: prevalence in worldwide populations. *Endocrinol Metab Clin North Am* 33: 351-375.
 11. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, et al. (2008) The metabolic syndrome. *Endocr Rev* 29: 777-822.
 12. Császár A, Kékes E, Abel T, Papp R, Kiss I, et al. (2006) Prevalence of metabolic syndrome estimated by International Diabetes Federation criteria in a Hungarian population. *Blood Press* 15: 101-116.
 13. Das D, Bora K, Baruah B, Konwar G (2017) Prevalence and predictors of metabolic syndrome in schizophrenia patients from Assam. *Indian J Psychiatry* 59: 228-232.
 14. Deepa M, Farooq S, Datta M, Deepa R, Mohan V (2007) Prevalence of metabolic syndrome using WHO, ATP III and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). *Diabetes Metab Res Rev* 23:127-134.
 15. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP (2007) Pathophysiology and types of dyslipidemia in PCOS. *Trends Endocrinol Metab* 18: 280-285.
 16. do Carmo I, Dos Santos O, Camolas J, Vieira J, Carreira M, et al. (2008) Overweight and obesity in Portugal: national prevalence in 2003-2005. *Obes Rev* 9: 11-19.
 17. Ervin RB (2009) Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. *Natl Health Stat Report* 5: 1-7.
 18. Expert Panel on Detection (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA* 16: 2486-297.
 19. Fiuzza M, Cortez-Dias N, Martins S, Belo A (2008) Metabolic syndrome in Portugal: prevalence and implications for cardiovascular risk--results from the VALSIM Study. *Rev Port Cardiol* 27: 1495-1529.
 20. Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. *Atherosclerosis* 173: 307-312.
 21. Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. *Diabetes Care* 28: 1769-1778.
 22. Ford ES, Li C, Zhao G (2010) Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. *J Diabetes* 2: 180-193.
 23. Giugliano D, Ceriello A, Esposito K (2006) The effects of diet on inflammation: emphasis on the metabolic syndrome. *J Am Coll Cardiol* 48: 677-685.
 24. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 109: 433-438.
 25. Harzallah F, Alberti H, Ben Khalifa F (2006) The metabolic syndrome in an Arab population: a first look at the new International Diabetes Federation criteria. *Diabet Med* 23: 441-444.
 26. Hillier TA, Fagot-Campagna A, Eschwège E, Vol S, Cailleau M (2006) Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the D.E.S.I.R. cohort. *Int J Epidemiol* 35: 190-196.
 27. Hollman G, Kristenson M (2008) The prevalence of the metabolic syndrome and its risk factors in a middle-aged Swedish population-mainly a function of overweight? *Eur J Cardiovasc Nurs* 7: 21-26.
 28. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, et al. (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. *Arch Intern Med* 164: 1066-1076.
 29. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, et al. (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. *Circulation* 110: 1251-1257.
 30. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 24: 683-689.
 31. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 288: 2709-2716.
 32. LeRoith D, Taylor SI, Olefsky JM (2004) *Diabetes Mellitus: A Fundamental and Clinical Text*. Lippincott Williams & Wilkins.
 33. Ma WY, Li HY, Hung CS, Lin MS, Chiu FC, et al. (2009) Metabolic syndrome defined by IDF and AHA/NHLBI correlates better to carotid intima-media thickness than that defined by NCEP ATP III and WHO. *Diabetes Res Clin Pract* 85: 335-341.
 34. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, et al. (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. *Diabetes Care* 28: 385-390.
 35. Misra A, Khurana L (2008) Obesity and the metabolic syndrome in developing countries. *J Clin Endocrinol Metab* 93: S9-30.
 36. Mottilo S, Filion KB, Genest J, Joseph L, Pilote L, et al. (2010) The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. *J Am Coll Cardiol* 56: 1113-1132.
 37. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, et al. (2004) High prevalence of metabolic syndrome in Mexico. *Arch Med Res* 35: 76-81.
 38. Reaven GM (1988) Role of Insulin Resistance in Human Disease. *Diabetes* 37: 1595-1607.
 39. Sharifi F, Mousavinasab SN, Saeini M, Dinmohammadi M (2009) Prevalence of metabolic syndrome in an adult urban population of the west of Iran. *Exp Diabetes Res* 2009: 136501.
 40. Timóteo A, Santos R, Lima S, Mamede A, Fernandes R, et al. (2009) Does the new International Diabetes Federation definition of metabolic syndrome improve prediction of coronary artery disease and carotid intima-media thickening? *Rev Port Cardiol* 28: 173-181.
 41. Zabetian A, Hadaegh F, Azizi F (2007) Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATP III and the WHO definitions. *Diabetes Res Clin Pract* 77: 251-257.
 42. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, et al. (2002) Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. *Am J Clin Nutr* 76:743-749.